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Mycobacterium tuberculosis (Mtb), the aetiological agent of Human Tuberculosis (TB), is an 
intracellular pathogen. According to the World Heath Organisation, 1.8 billion people are infected and 
approximately 1.3 million people die from Tuberculosis annually. The global prevalence of TB is 
sustained by the ongoing HIV-AIDS pandemic and the alarming increase of antibiotic resistant Mtb 
isolates(1). As a successful intracellular pathogen targeting macrophages, nutrient acquisition is a key 
feature to establish infection within the phagosome, a nutritionally-constrained environment (2, 3), and 
in this issue of Virulence, Ramón-Garcia et al demonstrate that the P55 efflux pump is required for 
optimal mycobacterial growth on cholesterol(4).  
Most bacteria are subject to catabolite repression which is a widespread regulatory trait by 
which bacteria maximize growth by consuming individual carbon substrates in a preferred sequence. 
However Mtb does not follow the same rules. de Carvalho et al demonstrated that Mtb has the ability 
to co-catabolize different carbon sources such acetate, dextrose and glycerol, and that each component 
carbon source has a distinct metabolic fate, leading to enhanced monophasic growth(5). Effectively, by 
using a combination of stable isotope labelling and state-of-art liquid-chromatography accurate mass-
spectrometry, de Carvalho et al demonstrated that during growth on carbon sources mixtures, Mtb 
metabolized each component carbon source to a distinct metabolic fate. For example, during growth on 
an equimolar mixture of dextrose and acetate, Mtb preferentially metabolized dextrose into glycolytic 
and pentose phosphate pathway intermediates while directing acetate into intermediates of the 
tricarboxylic acid cycle (TCA cycle). Appelberg et al noted that intracellular pathogens like Mtb must 
acquire nutrients while surrounded by host-derived lipids(6), and it has been proposed that they may be 
utilized as carbon source(7). Several lines of evidence suggest that pathogenic mycobacteria primarily 
use fatty acids rather than carbohydrates as carbon substrates during infection(8). It is important to stress 
that cholesterol is a major structural component of animal cell membranes. Host cholesterol is thought 
to be involved in the development of Mtb infection(9), with a high level in the diet shown to 
significantly enhance bacterial burden in the lung(10) and impair immunity to Mtb(11). Further work 
indicates that cholesterol is not required for establishing infection but rather appears to be essential for 
persistence in the lungs and for growth within IFN-γ activated macrophages. Cholesterol acquisition 
and metabolism has been the topic of several investigations. The mce4 operon (mammalian cell entry 4 
transport system), is crucial for virulence in animal models and cholesterol uptake(12). The mce4 locus 
is one of four homologous regions in Mtb genome and consists of several genes predicted to encode a 
multi-subunit ABC-like transporter system(13). Senaratne et al demonstrated that mce4-mutants were 
attenuated in mice(12). Pandey and Sassetti performed a synthetic lethality screen and identified a 
number of genes located near the mce4 operon that appeared to function in concert with this 
transporter(13), demonstrating that deletion of the mce4 operon led to a marked growth defect when 
cholesterol was sole carbon source, as well as severely reduced accumulation of cholesterol compared 
to the wild-type(14). In addition, cholesterol is not only taken up by Mtb, but also catabolised. Pandey 
and Sassetti provides evidence of cholesterol degradation by monitoring from both 4- and 26-carbons 
of the molecule, with C-4 converted to CO2 and C-26 becoming incorporated to membrane lipids, 
including a major virulence-associated lipid, phthiocerol dimycocerosate(14, 15). This last finding has 
been supported by Griffin et al who describe that metabolic alterations observed during cholesterol 
catabolism are centred on propionyl-CoA and pyruvate pools(16), leading to transcriptional regulation 
of propionyl-CoA-assimilating methylcitrate cycle enzymes via Rv1129c regulatory proteins. The 
growth defect of methylcitrate cycle mutants is largely attributable to degradation of host-derived 
cholesterol(16). More recently, using an unbiased chemical screen to identify chemical compounds that 
inhibit Mtb metabolism within macrophages VanderVen et al isolated a compound that inhibits PrpC 
(Rv1131), the 2-methylcitrate synthase, which is required for assimilation of cholesterol-derived 
propionyl-CoA into the TCA cycle(17).  
In this issue of Virulence, Ramón-Garcia et al demonstrate the requirement for the 
mycobacterial P55 efflux pump for optimal growth on cholesterol(4). Previous work by Joshi et al 
reported that the gene encoding the P55 efflux pump (rv1410c) interacted positively with mce1 and 
mce4 gene clusters in vivo(13). This suggested a potential shared function for this efflux pump. P55 is 
a mycobacterial efflux pump belonging to the Major Facilitator Superfamily (MFS) of membrane 
transporters required for growth, maintenance of cellular redox balance, and export of some antibiotics, 
including first-line antibiotics(18, 19). It is important to stress that P55 is part of an operon with the 
LprG lipoprotein, encoded by the gene rv1411c. Bigi et al reported that deletion of the lprG-rv1410 
operon leads to a strong attenuation of Mtb in mice, suggesting a crucial role for these two genes in Mtb 
virulence(20). Gaur et al confirmed and defined that LprG is essential for Mtb virulence via mediating 
surface exposition of lipoarabinomannan (LAM)(21). LAM is critical for several important 
immunological process such as cell entry, inhibition of phagosome-lysosome fusion, and intracellular 
survival(22).  
Altogether, this article provides the first evidence for an efflux pump being involved in 
cholesterol uptake. However, defining the mechanism how P55 interacts synergistically with mce4 will 
provide a better understanding of this complex and essential process, new routes for antibiotics 
development and a better understanding of antimicrobial resistance. 
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